Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and Bilirubinemia

irinotecan has been researched along with Bilirubinemia in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (20.00)18.2507
2000's5 (50.00)29.6817
2010's2 (20.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Steventon, G1
Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI1
Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ1
Armand, JP; Boige, V; Ducreux, M; Faivre, S; Gatineau, M; Jacques, C; Raymond, E; Rixe, O; Sanderink, GJ; Vernillet, L1
Chung, G; Mehra, R; Murren, J; Psyrri, A; Smith, B1
Du, J; Feng, G; He, L; Li, X; Qin, S; Wang, L; Xing, Q; Xu, L; Xu, M; Yu, L; Zhang, A1
Fakih, MG; Gupta, B; LeVea, C; Litwin, A1
Kado, S; Kaneda, N; Kato, I; Kurita, A; Matsumoto, T; Onoue, M; Uchida, K; Yokokura, T1
Chu, XY; Hakusui, H; Kato, Y; Niinuma, K; Sudo, KI; Sugiyama, Y1
Chu, XY; Kato, Y; Sugiyama, Y1

Reviews

1 review(s) available for irinotecan and Bilirubinemia

ArticleYear
Uridine diphosphate glucuronosyltransferase 1A1.
    Xenobiotica; the fate of foreign compounds in biological systems, 2020, Volume: 50, Issue:1

    Topics: Alleles; Bilirubin; Genotype; Glucuronosyltransferase; Humans; Hydroxamic Acids; Hyperbilirubinemia; Irinotecan; Sulfonamides

2020

Trials

1 trial(s) available for irinotecan and Bilirubinemia

ArticleYear
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21

    Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Humans; Hyperbilirubinemia; Irinotecan; Male; Middle Aged; Predictive Value of Tests

2002

Other Studies

8 other study(ies) available for irinotecan and Bilirubinemia

ArticleYear
[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
    Voprosy onkologii, 2015, Volume: 61, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Incidence; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Genetic; Thrombocytopenia

2015
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
    American journal of clinical oncology, 2017, Volume: 40, Issue:6

    Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Camptothecin; Eligibility Determination; Female; Fluorouracil; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Insufficiency; Retrospective Studies

2017
Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cecal Neoplasms; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Irinotecan; Liver; Male; Neutropenia; Pharmacogenetics; Polymorphism, Genetic

2005
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.
    The pharmacogenomics journal, 2007, Volume: 7, Issue:5

    Topics: Adult; Antineoplastic Agents, Phytogenic; Asian People; Bilirubin; Bone Marrow Diseases; Camptothecin; China; Ethnicity; Exons; Female; Gastrointestinal Diseases; Gene Frequency; Genetic Predisposition to Disease; Glucuronosyltransferase; Haplotypes; Heterozygote; Homozygote; Humans; Hyperbilirubinemia; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Reference Values; TATA Box

2007
Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:6

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Polymorphism, Genetic

2007
Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:4

    Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Crigler-Najjar Syndrome; Diarrhea; Glucuronosyltransferase; Hyperbilirubinemia; Intestines; Irinotecan; Rats; Rats, Gunn; Rats, Wistar

2008
Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 281, Issue:1

    Topics: Adenosine Triphosphate; Animals; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; Bile; Bile Canaliculi; Camptothecin; Carrier Proteins; Hyperbilirubinemia; Irinotecan; Male; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley

1997
Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
    Cancer research, 1997, May-15, Volume: 57, Issue:10

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Biliary Tract; Camptothecin; Carboxylic Acids; Glutathione; Hyperbilirubinemia; Irinotecan; Lactones; Male; Rats; Rats, Sprague-Dawley

1997